Y
ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Lancet Oncol · 2026-11-01

In 160 transplant-ineligible adults with relapsed/refractory large B-cell lymphoma, CD20-CD19 CAR T-cell therapy zamto-cel lengthened event-free survival vs R-GemOx (median 6·21 vs 2·53 months; HR 0·39). Treatment-related deaths: 3% vs 1%.

RCTn = 160
Borchmann et al. Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study
Oncology · Lancet Oncol · 2026-09-25

In relapsed/refractory myeloma after 1–2 prior lines, iberdomide-daratumumab-dexamethasone raised MRD-negative complete response vs daratumumab-bortezomib-dexamethasone (41% vs 21%; OR 2·8). Grade 3–4 events 92% vs 70%; PFS still pending.

RCTn = 420
Lonial et al. Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.